Prof. Rui Xie 谢蕊
Chief Physician, Professor
Department of Gastroenterology, Harbin Medical University Cancer Hospital, Harbin
Public profile Compiled from public listings and PubMed. We do not work directly with this doctor, but we can find a specialist in this field to review your case.
Get a specialist opinionClinical focus: Chemotherapy, molecular targeted therapy, photodynamic therapy, and clinical trials for esophageal, gastric, liver, biliary, pancreatic, colorectal cancers, gastrointestinal stromal tumors, and liver metastases.
Dr. Xie is a Professor and Chief Physician at Harbin Medical University Cancer Hospital. Holding MD and PhD degrees from Harbin Medical University, Dr. Xie completed postdoctoral research in pharmacy and materials science. Former visiting scholar at Dartmouth College and clinical scholar at National University Hospital, Singapore, Dr. Xie focuses on oncology research and education.
Professional roles
- Standing Committee Member, Photodynamic Therapy Professional Committee, China Anti-Cancer Association
- Deputy Leader, Youth Group, Laser Medicine Branch, Chinese Medical Association
- Member, Smart Healthcare Professional Committee, China Association of Integrative Medicine
- Member, Photodynamic Therapy and Rehabilitation Professional Committee, Chinese Association of Rehabilitation Medicine
Name order: in Chinese the family name comes first (Xie Rui). Papers usually list the name as Rui Xie or Xie R.
Selected publications
28 papers on PubMed matched by name and affiliation; 11 as first or senior author since 2016. Most recent first- or senior-author papers:
- Sci Adv, 2026 (senior author): Piezobiomimetic delivery nanosystem converts cold tumors to hot by parallel PANoptosis/STING activation in hepatocellular carcinoma. PubMed 42308311
- Cell Biol Toxicol, 2025 (senior author): CUL1-neddylation contributes to K29-linked ubiquitination on p27 for autophagic degradation in sorafenib-resistant liver cancer. PubMed 40111576
- Front Oncol, 2024 (senior author): Mean platelet volume/platelet count ratio can predict the recurrence-free survival rate of patients after complete resection of gastrointestinal stromal tumors. PubMed 39582542
- Cancer Med, 2024 (senior author): Meaningful nomograms based on systemic immune inflammation index predicted survival in metastatic pancreatic cancer patients receiving chemotherapy. PubMed 38986683
- Funct Integr Genomics, 2023 (senior author): Development and validation a prognostic model based on natural killer T cells marker genes for predicting prognosis and characterizing immune status in glioblastoma through integrated analysis of single-cell and bulk RNA sequencing. PubMed 37650991
- BMC Cancer, 2023 (senior author): Comprehensive analysis identifies cuproptosis-related gene DLAT as a potential prognostic and immunological biomarker in pancreatic adenocarcinoma. PubMed 37330494
- Cancer Biomark, 2021 (senior author): Significant difference of c-type lectin-like receptor 2 between colorectal cancer and polyp subgroups. PubMed 33554888
- Artif Cells Nanomed Biotechnol, 2020 (senior author): 5-Aminolevulinic acid hydrochloride loaded microbubbles-mediated sonodynamic therapy in pancreatic cancer cells. PubMed 32924612
See the full PubMed search. Automatic matching can miss papers or include a namesake at the same hospital. This name is shared by other researchers, so we checked that the papers match this doctor's specialty; this check is automatic.
This profile has not been reviewed by the doctor. How we build this directory.
Want a specialist to review your case?
Send your records. We find a specialist in this field who can review your case and write a treatment plan with a cost estimate.
Get a specialist opinion